Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;269(1):55-58.
doi: 10.1007/s00415-021-10648-w. Epub 2021 Jun 11.

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Joachim Havla  1   2 , Yannick Schultz  3 , Hanna Zimmermann  4 , Reinhard Hohlfeld  5   6 , Adrian Danek  3 , Tania Kümpfel  5
Affiliations

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine

Joachim Havla et al. J Neurol. 2022 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

J. Havla reports grants for OCT research from the Friedrich-Baur-Stiftung and Merck, personal fees and non-financial support from Celgene, Merck, Alexion, Novartis, Roche, Santhera, Biogen, Heidelberg Engineering, Sanofi Genzyme and non-financial support of the Guthy-Jackson Charitable Foundation, all outside the submitted work. Y. Schultz, H. Zimmermann and A. Danek report no disclosures relevant to the manuscript. R. Hohlfeld received honoraria and grant support from Novartis, Sanofi, Biogen, Teva, Merck, JJ and Roche. T. Kümpfel has received travel expenses and personal compensation from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, Roche, and Biogen, as well as grant support from Bayer Schering AG, Novartis, and Chugai Pharma, all outside the submitted work.

Figures

Fig. 1
Fig. 1
Spinal MRI: a, b peripherally located, T2 hyperintense lesion at level T6 and T7. The craniocaudal extension is less than two vertebral body segments. c Contrast enhancement after application of gadolinium is consistent with an active lesion. Thus, the criteria of spatial dissemination are fullfilled
Fig. 2
Fig. 2
Cranial MRI performed one week after spinal MRI (Fig. 1). 3D FLAIR with 1 mm slice thickness and reconstruction in three planes. a The sagittal image shows a lesion in the splenium of the corpus callosum. b Axial image shows a periventricular lesion with triangular configuration. c Coronal image depicts a juxtacortical lesion involving the U-fibers. d Axial image shows involvement of the cerebellum. Overall, the MRI showed more than 20 specific lesions larger than 3 mm at periventricular, cortical/juxtacortical, or infratentorial locations without contrast enhancement
See this image and copyright information in PMC

References

    1. Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M, Musc-19 Study G (2021) Disease-Modifying Therapies and Coronavirus Disease 2019 severity in multiple sclerosis. Ann Neurol 89:780-789. 10.1002/ana.26028 - PMC - PubMed
    1. Reyes S, Ramsay M, Ladhani S, Amirthalingam G, Singh N, Cores C, Mathews J, Lambourne J, Marta M, Turner B, Gnanapavan S, Dobson R, Schmierer K, Giovannoni G. Protecting people with multiple sclerosis through vaccination. Pract Neurol. 2020;20:435–445. doi: 10.1136/practneurol-2020-002527. - DOI - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O'Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Torok ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford CVTG. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Diem L, Friedli C, Chan A, Salmen A, Hoepner R. Vaccine hesitancy in patients with multiple sclerosis: preparing for the SARS-CoV-2 vaccination challenge. Neurol Neuroimmunol Neuroinflammation. 2021 doi: 10.1212/NXI.0000000000000991. - DOI - PMC - PubMed
    1. Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M. COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by February 2021. Mult Scler. 2021;27:864–870. doi: 10.1177/13524585211003476. - DOI - PMC - PubMed